Global Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 – 2024)
EXECUTIVE SUMMARY
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Prader-Willi Syndrome market. The report analyses the Global Prader-Willi Syndrome Therapeutics Market in terms of its sizing, growth and forecast. The report presents a comprehensive pipeline assessment that includes DCCR (Soleno Therapeutics), Levolitide (Millendo Therapeutics) and Tesomet (Saniona). Also, the report analyzes the prevalence of PWS and profiles the leading companies operating in the PWS Therapeutics market. The report analyzes the Global Market, European Region Market and the country analysis of United States and Japan for the historical period of 2017 and 2018 and the forecast period of 2019-2024.
According to Azoth Analytics research report, the Prader-Willi Syndrome therapeutics market is projected to display a robust growth represented by a CAGR of 4.6% during 2019 – 2024.
Over the recent years, the Prader-Willi Syndrome market has been witnessing considerable growth directly on the back of the increasing number of diagnosed patient’s population. Moreover, growing human growth hormone therapy coverage rate, surging awareness and increasing government involvement have been driving the market.
Further, expected launch of novel therapies, such as DCCR (Soleno Therapeutics), Livoletide (Millendo Therapeutics), Testomet (Saniona AB) among others are anticipated to fuel the market growth.
The report titled report “Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 – 2024)” has covered and analyzed the potential of Prader-Willi Syndrome market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges, opportunities and market entry strategies for various companies. Additionally, the report also highlights the estimated prevalence of Prader-Willi Syndrome in USA, Europe and Japan.
SCOPE OF THE REPORT
Global Prader-Willi Syndrome Market (Actual Period: 2017-2018, Forecast Period: 2019-2024)
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Prader-Willi Syndrome market. The report analyses the Global Prader-Willi Syndrome Therapeutics Market in terms of its sizing, growth and forecast. The report presents a comprehensive pipeline assessment that includes DCCR (Soleno Therapeutics), Levolitide (Millendo Therapeutics) and Tesomet (Saniona). Also, the report analyzes the prevalence of PWS and profiles the leading companies operating in the PWS Therapeutics market. The report analyzes the Global Market, European Region Market and the country analysis of United States and Japan for the historical period of 2017 and 2018 and the forecast period of 2019-2024.
According to Azoth Analytics research report, the Prader-Willi Syndrome therapeutics market is projected to display a robust growth represented by a CAGR of 4.6% during 2019 – 2024.
Over the recent years, the Prader-Willi Syndrome market has been witnessing considerable growth directly on the back of the increasing number of diagnosed patient’s population. Moreover, growing human growth hormone therapy coverage rate, surging awareness and increasing government involvement have been driving the market.
Further, expected launch of novel therapies, such as DCCR (Soleno Therapeutics), Livoletide (Millendo Therapeutics), Testomet (Saniona AB) among others are anticipated to fuel the market growth.
The report titled report “Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 – 2024)” has covered and analyzed the potential of Prader-Willi Syndrome market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges, opportunities and market entry strategies for various companies. Additionally, the report also highlights the estimated prevalence of Prader-Willi Syndrome in USA, Europe and Japan.
SCOPE OF THE REPORT
Global Prader-Willi Syndrome Market (Actual Period: 2017-2018, Forecast Period: 2019-2024)
- Prader-Willi Syndrome Market – Size, Growth, Forecast
- Prader-Willi Syndrome Market: Pipeline Analysis
- DCCR (Soleno Therapeutics)
- Levolitide (Millendo Therapeutics)
- Tesomet (Saniona)
- Prader-Willi Syndrome Market – Size, Growth, Forecast
- Prader-Willi Syndrome Market: Pipeline Analysis
- DCCR (Soleno Therapeutics)
- Levolitide (Millendo Therapeutics)
- Tesomet (Saniona)
- Pipeline Analysis.
- Competitive Landscape.
- Product Benchmarking.
- Market Dynamics – Drivers and Restraints.
- Market Trends.
- Porter Five Forces Analysis.
- SWOT Analysis.
- Company Analysis – Pfizer, Novartis, Novo Nordisk, Soleno Therapeutics, Saniona
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
3.1 Invest in Somatropin Biosimilar
3.2 Invest in Combination Therapy For PWS
4. SURGICAL MASKS PRODUCT OUTLOOK
5. GLOBAL PRADER-WILLI SYNDROME MARKET: GROWTH AND FORECAST
5.1 By Value (2017-2018)
5.2 By Value (2019-2024)
6. GLOBAL PRADER-WILLI SYNDROME PIPELINE ANALYSIS
6.1 DCCR Pipeline Analysis
6.2 Levolitide Pipeline Analysis
6.3 Tesomet Pipeline Analysis
7. GLOBAL PRADER-WILLI SYNDROME MARKET, BY REGION
8. U.S.A PRADER-WILLI SYNDROME MARKET
8.1 U.S.A Prader-Willi Syndrome Market Size (2017-2024F)
8.2 U.S.A Prader-Willi Syndrome Prevalence (2017-2024F)
9. EUROPE PRADER-WILLI SYNDROME MARKET
9.1 Europe Prader-Willi Syndrome Market Size (2017-2024F)
9.2 Europe Prader-Willi Syndrome Prevalence (2017-2024F)
10. JAPAN PRADER-WILLI SYNDROME MARKET
10.1 Japan Prader-Willi Syndrome Market Size (2017-2024F)
10.2 Japan Prader-Willi Syndrome Prevalence (2017-2024F)
11. GLOBAL PRADER-WILLI SYNDROME MARKET - COMPETITIVE LANDSCAPE
12. GLOBAL PRADER-WILLI SYNDROME MARKET - PRODUCT BENCHMARKING
13. GLOBAL PRADER-WILLI SYNDROME MARKET: MARKET DYNAMICS
13.1 Global Prader-Willi Syndrome Market Drivers
13.2 Global Prader-Willi Syndrome Market Restrains
13.3 Global Prader-Willi Syndrome Market Trends
14. PORTER FIVE FORCE ANALYSIS
15. SWOT ANALYSIS
16. GLOBAL PRADER-WILLI SYNDROME MARKET: REGULATORY FRAMEWORKS
17. COMPANY PROFILES
17.1 Pfizer
17.2 Novartis AG
17.3 Novo Nordisk
17.4 Soleno Therapeutics
17.4 Saniona
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
3.1 Invest in Somatropin Biosimilar
3.2 Invest in Combination Therapy For PWS
4. SURGICAL MASKS PRODUCT OUTLOOK
5. GLOBAL PRADER-WILLI SYNDROME MARKET: GROWTH AND FORECAST
5.1 By Value (2017-2018)
5.2 By Value (2019-2024)
6. GLOBAL PRADER-WILLI SYNDROME PIPELINE ANALYSIS
6.1 DCCR Pipeline Analysis
6.2 Levolitide Pipeline Analysis
6.3 Tesomet Pipeline Analysis
7. GLOBAL PRADER-WILLI SYNDROME MARKET, BY REGION
8. U.S.A PRADER-WILLI SYNDROME MARKET
8.1 U.S.A Prader-Willi Syndrome Market Size (2017-2024F)
8.2 U.S.A Prader-Willi Syndrome Prevalence (2017-2024F)
9. EUROPE PRADER-WILLI SYNDROME MARKET
9.1 Europe Prader-Willi Syndrome Market Size (2017-2024F)
9.2 Europe Prader-Willi Syndrome Prevalence (2017-2024F)
10. JAPAN PRADER-WILLI SYNDROME MARKET
10.1 Japan Prader-Willi Syndrome Market Size (2017-2024F)
10.2 Japan Prader-Willi Syndrome Prevalence (2017-2024F)
11. GLOBAL PRADER-WILLI SYNDROME MARKET - COMPETITIVE LANDSCAPE
12. GLOBAL PRADER-WILLI SYNDROME MARKET - PRODUCT BENCHMARKING
13. GLOBAL PRADER-WILLI SYNDROME MARKET: MARKET DYNAMICS
13.1 Global Prader-Willi Syndrome Market Drivers
13.2 Global Prader-Willi Syndrome Market Restrains
13.3 Global Prader-Willi Syndrome Market Trends
14. PORTER FIVE FORCE ANALYSIS
15. SWOT ANALYSIS
16. GLOBAL PRADER-WILLI SYNDROME MARKET: REGULATORY FRAMEWORKS
17. COMPANY PROFILES
17.1 Pfizer
17.2 Novartis AG
17.3 Novo Nordisk
17.4 Soleno Therapeutics
17.4 Saniona
LIST OF FIGURES
Figure 1: Global Prader-Willi Syndrome Market Size, By Value, 2017-2018 (USD Million)
Figure 2: Global Prader-Willi Syndrome Market Size, By Value, 2019F-2024F (USD Million)
Figure 3: Global Genotropin Sales, 2014-2014
Figure 4: Global Norditropin Sales, 2014-2014
Figure 5: Causes of Mortality in PWS Patients
Figure 6: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
Figure 7: Expected Global Medical Spending in 2020, By Region, (% of Total)
Figure 8: Global Life Expectancy At Birth For Selected Periods
Figure 9: Life Expectancy at Birth For Selected Periods, By Region
Figure 10: Projected global population (In Billions)
Figure 11: Projected global population aged 60 years & above (In Billions)
Figure 12: GDP Per Capita PPP, By Select Countries, 2022F (USD)
Figure 13: Healthcare Expenditure (Share of GDP), By Select Country, 2013-2018 (In %)
Figure 14: Global Expected Healthcare Industry Outlook
Figure 15: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 16: DCCR, Clinical Study Status
Figure 17: DCCR, Estimated US Market Value, According to Price and Penetration Rate, In USD Million
Figure 18: DCCR, Mean US Market Value, By Price and Penetration Rate, In USD Million
Figure 19: Livoletide, Clinical Study Status
Figure 20: Livoletide, Estimated US Market Value, In USD Million
Figure 21: Livoletide, Estimated US Cost Per Patient Annually, In USD Million
Figure 22: Tesomet, Clinical Study Status
Figure 23: Tesomet Timeline For PWS
Figure 24: Tesomet , US Expected Sales
Figure 25: Tesomet , US Expected Sales
Figure 26: Global Prader-Willi Syndrome Market Size, By Region, 2018, (%)
Figure 27: Global Prader-Willi Syndrome Market Size, By Region, 2024, (%)
Figure 28: USA Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
Figure 29: USA Prader-Willi Syndrome Prevalence, 2017-2024E
Figure 30: Mean Total Care Costs of Patients with PWS and Matched Controls
Figure 31: PWA (USA) Funds Split
Figure 32: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
Figure 33: Medical and Healthcare Research & Development Spending, 2013-2018 (In USD Billion)
Figure 34: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Figure 35: Europe Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
Figure 36: Europe Prader-Willi Syndrome Prevalence, 2017-2024E
Figure 37: Europe Union, Proportion of population aged 65 and over, 2014-2018 (% of Total Population)
Figure 38: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
Figure 39: GDP (Current USD), Europe Region, By Select Country, 2014-2018 (In Trillion USD)
Figure 40: Germany, Federal Government R&D Spending, 2017
Figure 41: Germany, Government R&D Spending on Health Research and Industry, (Euro Million), 2017
Figure 42: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Figure 43: France, Health Infrastructure, 2017
Figure 44: France, Healthcare Infrastructure Related Statistics
Figure 45: France, Spending on Healthcare, 2015 & 2040,(USD Per Person)
Figure 46: U.K, Health Expenditure, (% of GDP), 2014-2017 (USD)
Figure 47: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 48: Japan Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
Figure 49: Japan Prader-Willi Syndrome Prevalence, 2017-2024E
Figure 50: Japan Healthcare Expenditure Outlook (%)
Figure 51: Japan, Population, 2014-2017
Figure 52: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 53: Japan, Population ages 65 and above, 2012-2018 (% of total)
Figure 54: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 55: Japan, Population ages 65 and above, 2012-2018 (% of total)
Figure 56: Pfizer, Net Sales, 2014-2018 (USD Million)
Figure 57: Pfizer, Revenue, By Segments, 2018 (%)
Figure 58: Pfizer, Revenue, By Region, 2018 (%)
Figure 59: Novartis, Net Sales, 2013-2017 (USD Million)
Figure 60: Novartis, Revenue, By Segment, 2018(%)
Figure 61: Novartis, Revenue, By Region, 2018(%)
Figure 62: Novo Nordisk, Net Sales, 2014-2018 (In Million USD)
Figure 63: Novo Nordisk, Net Sales, By Business Sector, 2018 (In %)
Figure 64: Novo Nordisk, Net Sales, By Geographic Region, 2018 (In %)
Figure 65: Saniona, Net Sales, 2014-2018 (In Million USD)
Figure 66: Saniona, Drugs in Development, 2018
Table of Content
Table A: Somatropin Biosimilars For GHD and PWS
Table B: Genetic Therapies In Development For Prader-Willi Syndrome
Table C: Hyperphagia / Obesity Drugs In Development For Prader-Willi Syndrome
Table D: Behavior and Appetite Drugs In Development For Prader-Willi Syndrome
Table E: Muscle Development Therapies In Development For Prader-Willi Syndrome
Table F: PWS Mean Age Of Death, By Cause
Table G: Rare Disease Definitions Across Geographic Regions
Table H: DCCR, Trail Details
Table I: DCCR, US Market Analysis
Table J: Livoletide, Trail Details
Table K: Livoletide, US Market Analysis
Table L: Tesomet Trail Details
Table M: Tesomet , US Market Analysis
Table N: Tesomet , EU Market Analysis
Table O: Unites States, Hospitals Related Statistics, In 2018
Table P: Unites States, Number of Leading Drug Stores, In 2017
Table Q: Europe, Availability of Somatropin, By Country
Table R: EU-5 Socio-Economical Statistics, 2018
Table S: Germany, Hospitals Relates Statistics, 2017
Table T: Germany, Number of leading drug store chain, 2018
Table U: Germany, Pharmacies Related Statistics, 2017
Table V: Japan Healthcare System Outlook, 2017
Table W: Competitive Landscape of Selected Drugs In Development
Table X: Human Growth Hormone Products For PWS, By Company
Figure 1: Global Prader-Willi Syndrome Market Size, By Value, 2017-2018 (USD Million)
Figure 2: Global Prader-Willi Syndrome Market Size, By Value, 2019F-2024F (USD Million)
Figure 3: Global Genotropin Sales, 2014-2014
Figure 4: Global Norditropin Sales, 2014-2014
Figure 5: Causes of Mortality in PWS Patients
Figure 6: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
Figure 7: Expected Global Medical Spending in 2020, By Region, (% of Total)
Figure 8: Global Life Expectancy At Birth For Selected Periods
Figure 9: Life Expectancy at Birth For Selected Periods, By Region
Figure 10: Projected global population (In Billions)
Figure 11: Projected global population aged 60 years & above (In Billions)
Figure 12: GDP Per Capita PPP, By Select Countries, 2022F (USD)
Figure 13: Healthcare Expenditure (Share of GDP), By Select Country, 2013-2018 (In %)
Figure 14: Global Expected Healthcare Industry Outlook
Figure 15: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 16: DCCR, Clinical Study Status
Figure 17: DCCR, Estimated US Market Value, According to Price and Penetration Rate, In USD Million
Figure 18: DCCR, Mean US Market Value, By Price and Penetration Rate, In USD Million
Figure 19: Livoletide, Clinical Study Status
Figure 20: Livoletide, Estimated US Market Value, In USD Million
Figure 21: Livoletide, Estimated US Cost Per Patient Annually, In USD Million
Figure 22: Tesomet, Clinical Study Status
Figure 23: Tesomet Timeline For PWS
Figure 24: Tesomet , US Expected Sales
Figure 25: Tesomet , US Expected Sales
Figure 26: Global Prader-Willi Syndrome Market Size, By Region, 2018, (%)
Figure 27: Global Prader-Willi Syndrome Market Size, By Region, 2024, (%)
Figure 28: USA Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
Figure 29: USA Prader-Willi Syndrome Prevalence, 2017-2024E
Figure 30: Mean Total Care Costs of Patients with PWS and Matched Controls
Figure 31: PWA (USA) Funds Split
Figure 32: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
Figure 33: Medical and Healthcare Research & Development Spending, 2013-2018 (In USD Billion)
Figure 34: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Figure 35: Europe Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
Figure 36: Europe Prader-Willi Syndrome Prevalence, 2017-2024E
Figure 37: Europe Union, Proportion of population aged 65 and over, 2014-2018 (% of Total Population)
Figure 38: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
Figure 39: GDP (Current USD), Europe Region, By Select Country, 2014-2018 (In Trillion USD)
Figure 40: Germany, Federal Government R&D Spending, 2017
Figure 41: Germany, Government R&D Spending on Health Research and Industry, (Euro Million), 2017
Figure 42: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Figure 43: France, Health Infrastructure, 2017
Figure 44: France, Healthcare Infrastructure Related Statistics
Figure 45: France, Spending on Healthcare, 2015 & 2040,(USD Per Person)
Figure 46: U.K, Health Expenditure, (% of GDP), 2014-2017 (USD)
Figure 47: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 48: Japan Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
Figure 49: Japan Prader-Willi Syndrome Prevalence, 2017-2024E
Figure 50: Japan Healthcare Expenditure Outlook (%)
Figure 51: Japan, Population, 2014-2017
Figure 52: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 53: Japan, Population ages 65 and above, 2012-2018 (% of total)
Figure 54: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 55: Japan, Population ages 65 and above, 2012-2018 (% of total)
Figure 56: Pfizer, Net Sales, 2014-2018 (USD Million)
Figure 57: Pfizer, Revenue, By Segments, 2018 (%)
Figure 58: Pfizer, Revenue, By Region, 2018 (%)
Figure 59: Novartis, Net Sales, 2013-2017 (USD Million)
Figure 60: Novartis, Revenue, By Segment, 2018(%)
Figure 61: Novartis, Revenue, By Region, 2018(%)
Figure 62: Novo Nordisk, Net Sales, 2014-2018 (In Million USD)
Figure 63: Novo Nordisk, Net Sales, By Business Sector, 2018 (In %)
Figure 64: Novo Nordisk, Net Sales, By Geographic Region, 2018 (In %)
Figure 65: Saniona, Net Sales, 2014-2018 (In Million USD)
Figure 66: Saniona, Drugs in Development, 2018
Table of Content
Table A: Somatropin Biosimilars For GHD and PWS
Table B: Genetic Therapies In Development For Prader-Willi Syndrome
Table C: Hyperphagia / Obesity Drugs In Development For Prader-Willi Syndrome
Table D: Behavior and Appetite Drugs In Development For Prader-Willi Syndrome
Table E: Muscle Development Therapies In Development For Prader-Willi Syndrome
Table F: PWS Mean Age Of Death, By Cause
Table G: Rare Disease Definitions Across Geographic Regions
Table H: DCCR, Trail Details
Table I: DCCR, US Market Analysis
Table J: Livoletide, Trail Details
Table K: Livoletide, US Market Analysis
Table L: Tesomet Trail Details
Table M: Tesomet , US Market Analysis
Table N: Tesomet , EU Market Analysis
Table O: Unites States, Hospitals Related Statistics, In 2018
Table P: Unites States, Number of Leading Drug Stores, In 2017
Table Q: Europe, Availability of Somatropin, By Country
Table R: EU-5 Socio-Economical Statistics, 2018
Table S: Germany, Hospitals Relates Statistics, 2017
Table T: Germany, Number of leading drug store chain, 2018
Table U: Germany, Pharmacies Related Statistics, 2017
Table V: Japan Healthcare System Outlook, 2017
Table W: Competitive Landscape of Selected Drugs In Development
Table X: Human Growth Hormone Products For PWS, By Company
